ECE2019 Guided Posters Calcium and Bone 2 (11 abstracts)
Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1
Anca Zimmermann 1 , Radu Popp 2 , Heidi Rossmann 3 , Simona Bucerzan 4 , Ioana Nascu 4 , Daniel Leucuta 5 , Matthias Weber 1 & Paula Grigorescu-Sido 4
1University Medical Center Mainz, 1. Med. Clinic, Department of Endocrinology and Metabolic Diseases, Mainz, Germany; 2University of Medicine and Pharmacy Iuliu Hatieganu, Department of Medical Genetics, Cluj, Romania; 3University Medical Center Mainz, Institute for Clinical Chemistry and Laboratory Medicine, Mainz, Germany; 4University of Medicine and Pharmacy Iuliu Hatieganu, Center of Genetic Diseases, 1st Pediatric Clinic, Cluj, Romania; 5University of Medicine and Pharmacy Iuliu Hatieganu, Department of Medical Informatics and Biostatistics, Cluj, Romania.
Purpose: Osteopathy/osteoporosis in Gaucher disease type 1 (GD1) shows variable responses to enzyme replacement therapy (ERT); the pathogenesis is incompletely understood. We aimed to investigate the effect of several gene variants on bone mineral density (BMD) and serum markers of bone metabolism in GD1.
Patients/methods: 50 adult Caucasian patients with GD1/117 controls were genotyped for gene variants in the osteoprotegerin (TNFRSF11B; OPG), estrogen receptor alpha (ESR1), calcitonin receptor (CALCR), vitamin D receptor (VDR) genes. In patients and 50 matched healthy controls, we assessed: clinical data, serum markers of bone metabolism, subclinical inflammation. BMD was measured for the first time before/during ERT (median 6.7 years).
Results: 42% of patients were splenectomized. ERT led to variable improvements in BMD. Distribution of gene variants was comparable between patients/controls. The AA genotype (c.1024+283G>A gene variant; VDR gene) was associated with lower Z scores before ERT vs. GA (P=0.033), was encountered in 82.3% of patients with osteoporosis and was more frequent in patients with pathological fractures. Z score increases during ERT were higher in patients with the CC genotype (c.9C>G variant, TNFRSF11B; OPG gene) compared to GC (P=0.003). The CC genotype (c.1340T>C variant, CALCR gene) was associated with higher Z scores before ERT than the TT genotype (P=0.041) and was absent in osteoporosis. Osteocalcin and osteoprotegerin were lower in patients vs. controls; beta crosslaps, interleukin-6, ferritin were higher.
Conclusions: We suggest for the first time a protective role against osteoporosis in GD1 patients for the CC genotype of the c.9C>G gene variant in the TNFRSFB11 (OPG) gene and for the CC genotype of the c. 1340T>C gene variant (CALCR gene), while the AA genotype of the c.1024+283G>A gene variant in the VDR gene appears as a risk factor for lower BMDs. Serum markers suggest decreased osteosynthesis, reduced inhibition of osteoclast activation, increased bone resorption and subclinical inflammation during ERT.
Volume 63
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more